Abeona Therapeutics Inc.
ABEO
$6.91
-$0.04-0.58%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -34.44% | 37.94% | 9.74% | 31.44% | -8.71% |
Gross Profit | 38.78% | -37.94% | -9.74% | -31.44% | -39.71% |
SG&A Expenses | 98.35% | 37.39% | 31.70% | 54.09% | 72.20% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 29.83% | 37.66% | 26.22% | 35.39% | 18.16% |
Operating Income | -27.59% | -37.66% | -26.22% | -35.39% | -53.75% |
Income Before Tax | 1,578.98% | 61.91% | 43.99% | -155.74% | 144.47% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | 1,369.52% | 61.91% | 43.99% | -155.74% | 144.47% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 1,369.52% | 61.91% | 43.99% | -155.74% | 144.47% |
EBIT | -27.59% | -37.66% | -26.22% | -35.39% | -53.75% |
EBITDA | -28.03% | -38.69% | -26.85% | -37.41% | -57.92% |
EPS Basic | 1,019.39% | 79.10% | 70.44% | -31.89% | 120.03% |
Normalized Basic EPS | -388.16% | 79.10% | 70.35% | -31.91% | 118.83% |
EPS Diluted | 749.79% | 79.10% | 70.44% | -31.89% | 71.60% |
Normalized Diluted EPS | -390.71% | 79.10% | 70.35% | -31.91% | 114.71% |
Average Basic Shares Outstanding | 31.28% | 82.24% | 89.46% | 93.90% | 122.06% |
Average Diluted Shares Outstanding | 30.09% | 82.24% | 89.46% | 93.90% | 184.31% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |